Skip to content

The Effect of Prophylactic Hemodialysis on the Morbidity and Mortality of the Patients With Chronic Kidney Disease Stages 3-4 Undergoing Coronary Artery Graft Bypass

Status
UNKNOWN
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01410617
Enrollment
120
Registered
2011-08-05
Start date
2011-08-31
Completion date
2013-12-31
Last updated
2013-03-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Disease stage3, Chronic Kidney Disease stage4, Coronary Artery Disease

Brief summary

Coronary artery disease is a major cause of death in patients with renal dysfunction Among patients who undergo coronary artery bypass grafting ,renal dysfunction is known To be a major predictor of in-hospital and remote mortality As little is known about the impact of non-dialysis-dependent renal dysfunction on short and mid term Outcomes following coronary surgery we have decided to investigate the effect of prophylactic Hemodialysis on the mortality and morbidity of the patients with ckd (stage 3,4 ) and compare these Effect with the control group

Interventions

PROCEDUREhemodialysis

3 sessions hemodialysis before CABG

Sponsors

Tehran University of Medical Sciences
CollaboratorOTHER
Imam Khomeini Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* 80\<age\>18 * ckd patients with stage 3,4 * CABG for the first time

Exclusion criteria

* age\<18 * previous CABG (coronary artery bypass grafting) * AKI(acute kidney injury) * dialysis patients

Design outcomes

Primary

MeasureTime frameDescription
morbiditythe morbidity during the time of hospitalization until discharge (baseline) and six month latermorbidity is defined as length of hospitalization,infection rate,duration of mechanical ventilation,bleeding complications,

Secondary

MeasureTime frame
mortalityfrom the time of CABG (baseline) until six months later

Countries

Iran

Contacts

Primary ContactMohamamd R khatami, MD
khatamis@sina.tums.ac.ir00982161192659
Backup ContactRoghieh Borji, MD
soheila1111@yahoo.com009891254590988

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026